Livzon Pharmaceutical details A-share repurchase, H-share buyback pending

Livzon Pharmaceutical Group has announced the progress of its share repurchase program as of August 31, 2025. The company has repurchased 13,383,055 A-shares through concentrated bidding, representing 1.48% of its total share capital. The A-share buyback involved a total expenditure of CNY 490,929,437.15 (excluding transaction fees), with prices ranging from CNY 33.21 to CNY 41.99 per share. This A-share repurchase aligns with the company's previously approved plan to buy back shares for cancellation and reduction of registered capital.

The repurchases stem from resolutions passed at shareholder meetings in December 2024 and May 2025, which approved the A-share repurchase plan and granted a general mandate for H-share repurchases.

Regarding its H-share repurchase program under the general mandate, Livzon Pharmaceutical Group stated that as of August 31, 2025, no H-share repurchases have been executed. The company intends to conduct H-share repurchases on the Hong Kong Stock Exchange. These H-shares, once repurchased, will also be used for cancellation to reduce registered capital.